Open Access

ARTICLE

Integrative bioinformatics and in vitro exploration of EVI2A expression: unraveling its immunological and prognostic implications in kidney renal clear cell carcinoma

by RONG LIU^1,#, SHENG LI^2,#, SITU XIONG², FUCUN ZHENG², XIANGPENG ZHAN², JIN ZENG², BIN FU², SONGHUI XU², SHAOXING ZHU^1,*, RU CHEN^1,*

1 Department of Urology, Fujian Medical University Union Hospital, Fuzhou, 350000, China
2 Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, 350000, China

* Corresponding Authors: SHAOXING ZHU. Email: ; RU CHEN. Email:
# These authors contributed equally to this work

Oncology Research 2024, 32(11), 1733-1746. https://doi.org/10.32604/or.2024.050851

Received 25 September 2023; Accepted 22 February 2024; Issue published 16 October 2024

Abstract

EVI2A has emerged as a significant biomarker in various diseases; however, its biological role and mechanism in kidney renal clear cell carcinoma (KIRC) remains unexplored. We used TCGA and GEO databases to analyze EVI2A gene expression comprehensively and performed pan-cancer assessments. Clinical relevance was evaluated through Kaplan-Meier analysis and ROC curves. The gene’s immune relevance was explored through analyses of the tumor microenvironment (TME), Tumor Immune Single-cell Hub (TISCH), immune checkpoints, and immunotherapy sensitivity. Our results indicate that EVI2A expression is upregulated in KIRC, showing correlations with tumor grade and T/N/M stage. EVI2A demonstrates high diagnostic accuracy (AUC=0.906) and predicts poor overall and progression-free survival in KIRC patients. Furthermore, EVI2A expression exhibits significant associations with immunity, including TME scores and specific immune cell types such as Tfh cells, CD4 memory T cells, and CD8+ T cells. Elevated EVI2A expression suggests increased sensitivity to PD-1/CTLA-4 and tyrosine kinase inhibitors. In vitro assays confirmed the impact of EVI2A on KIRC behavior, with its knockdown resulting in reduced cell proliferation and migration. In conclusion, our comprehensive analysis identifies EVI2A as a promising biomarker and a novel therapeutic target for intervening in KIRC. These findings hold significant implications for further research and potential clinical applications.

---

Keywords

---

Supplementary Material

Supplementary Material File

---